12,211 Shares in Vaxcyte, Inc. $PCVX Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 12,211 shares of the company’s stock, valued at approximately $710,000.

A number of other hedge funds have also made changes to their positions in PCVX. Smartleaf Asset Management LLC increased its position in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the last quarter. Capital Advisors Ltd. LLC acquired a new stake in Vaxcyte during the 1st quarter worth $58,000. Finally, Allworth Financial LP acquired a new stake in Vaxcyte during the 2nd quarter worth $75,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on PCVX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vaxcyte has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $62.62 on Monday. The company’s 50-day moving average price is $56.43 and its 200-day moving average price is $55.79. The stock has a market cap of $9.32 billion, a price-to-earnings ratio of -8.21 and a beta of 1.23. Vaxcyte, Inc. has a twelve month low of $29.87 and a twelve month high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same quarter last year, the firm earned ($1.22) EPS. As a group, equities research analysts predict that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Insider Activity

In related news, CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the transaction, the chief financial officer directly owned 105,176 shares in the company, valued at approximately $5,667,934.64. This represents a 8.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $53.86, for a total value of $121,185.00. Following the sale, the chief operating officer directly owned 157,541 shares of the company’s stock, valued at approximately $8,485,158.26. This trade represents a 1.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 120,646 shares of company stock worth $6,570,810 in the last 90 days. 3.30% of the stock is owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.